

pharma.be
ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE



E-PIL

Belgium & Luxembourg Pioneer Pilot Project

London, the 28th of November



Why such a pilot project in Belgium and Luxembourg?

Convenience of electronic Patient Information Leaflet

- Continued access to the most recent information
- Personalised and user-friendly information



- Quick access and dissemination of the most recent information
- Personalised and user-friendly information

Supporting the mission of Public Health


Flexibility in update of the information, reducing product recalls

Reducing environmental impact (paper and production)

A specific context in Europe

- 2015: recommendations in Nivel Report
- European Commission report on improvement of product information

A specific context in Belgium and Luxembourg



- internet access up to 85%* in Be and to 97% in Lux**.
- use of social media (69%)*

2014: a survey in hospital pharmacists showed a wide use of electronic support for patient information



- 90% pro switch paper version to electronic version
- 44% use both the paper and the electronic version
- 55% only the electronic version

Source:

*<https://economie.fgov.be/fr/themes/line/les-tic-en-belgique/le-tic-en-chiffres>

** Lux Figures in 2015

***Survey conducted in 2014 with the help of pharma.be and the hospital pharmacists association; survey filled out by 199 respondents.

Objectives and outline of the pilot

The **package leaflet** for a selection of centrally approved medicinal products restricted to hospital use and marketed in Belgium and/or Luxembourg is **no longer included in their paper version but is available via online consultation of trusted websites**

CONCEPT

1

To demonstrate **e-PIL is equivalent to paper PIL** to provide information on safe and effective use of medicines to healthcare professionals and patients in the context of hospital used medicines

OBJECTIVE

2

- Only for a **selection of medicines** ± 15 medicines in different therapeutics areas
- Hospital-only
- NO ambulatory
- Central products only

SCOPE

3

Time-limited project of 24 months

Roadmap



Regulatory considerations



No more paper product information leaflet inserted in the package
⇒ Not in line with article 58 of EU Directive 2001/83/CE (implemented in Belgian and Luxembourg legislation)



2016-2017: Consultation and engagement of association hospital pharmacists



October 2017 – December 2017:

Request of Derogation to article 58 prepared by the BE & LUX authorities and submitted to EU commission

Conditions: limited number of medicines restricted to hospital setting; time limited project

Obtained in December 2017




April 2018 – June 2018:

Call for candidates supported by the BE & LUX authorities
Validation by the BE & LUX authorities of each proposed medicine as candidate

Practical setting and methodology


Operational setting



Online consultation of product information



Via Competent Authorities website & official commented list of medicines (CBIP-BCFI)



Via pharma.be e-notice

- Adaptive site
- Search engine
- Xml layout
- Chapter by chapter



Key performance indicators and follow-up of the pilot project



Steering committee:

- pharma industry representatives
- hospital pharmacists
- BE & LU competent authorities

KPIs

- Defined and monitored by the steering committee
- Survey in hospital pharmacists (t=0=baseline; t=12months; t=24months) to evaluate **the access, the use and the reading of electronic PILs** during the pilot project
 - Incl. capture of the feedback for the healthcare professionals in hospitals (nurses, physicians)
 - **Baseline survey during summer 2018: response rate: 100% Lux, 92% Be - Results under analysis**
- Survey for participating pharma companies (t=12months; t=24months) to evaluate the questions due to the absence of paper patient information leaflet in the packaging.

⇒ key outcomes to demonstrate:

- allow to provide sufficient, adequate and tailored (e.g. language) information to healthcare professionals and patients with no need to print the patient information
- positive impact on daily practice of hospital pharmacists

Thank you!

Nathalie Lambot



nl@pharma.be



0032471/92.76.27

Inge Vandenbulcke



inge.vandenbulcke@fagg.be



0032 2 528.40.00

Visit our website :

www.pharma.be

<https://www.famhp.be/en>

